Study of VB119 in focal segmental glomerulosclerosis

ValenzaBio, Inc is starting a new clinical trial of Efficacy and Safety of VB119 in Subjects With Minimal Change Disease and Focal Segmental Glomerulosclerosis.

Phase 2, multi-center, proof-of-concept study to evaluate the safety and efficacy of VB119 on the maintenance of remission and duration of response in adults with primary MCD or primary FSGS who previously responded to steroid therapy.

The clinical trial started in May 3, 2022 and will continue throughout February 28, 2024.

The proportion of subjects in remission at End of Treatment will be primary outcome measure. Efficacy.

For more details:

https://ichgcp.net/clinical-trials-registry/NCT05441826 or https://clinicaltrials.gov/ct2/show/NCT05441826.